These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15054690)

  • 1. [Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].
    Wuttke H; Rau T; Eschenhagen T
    Dtsch Med Wochenschr; 2004 Apr; 129(15):831-5. PubMed ID: 15054690
    [No Abstract]   [Full Text] [Related]  

  • 2. Carvedilol but not metoprolol reduces beta-adrenergic responsiveness after complete elimination from plasma in vivo.
    Kindermann M; Maack C; Schaller S; Finkler N; Schmidt KI; Läer S; Wuttke H; Schäfers HJ; Böhm M
    Circulation; 2004 Jun; 109(25):3182-90. PubMed ID: 15184276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoselective disposition of carvedilol is determined by CYP2D6.
    Zhou HH; Wood AJ
    Clin Pharmacol Ther; 1995 May; 57(5):518-24. PubMed ID: 7768074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.
    Baudhuin LM; Miller WL; Train L; Bryant S; Hartman KA; Phelps M; Larock M; Jaffe AS
    Am J Cardiol; 2010 Aug; 106(3):402-8. PubMed ID: 20643254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics and heart failure: a convergence with carvedilol.
    Meadowcroft AM; Williamson KM; Patterson JH; Pieper JA
    Pharmacotherapy; 1997; 17(4):637-9. PubMed ID: 9250542
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.
    Nozawa T; Taguchi M; Tahara K; Hashimoto Y; Igarashi N; Nonomura M; Kato B; Igawa A; Inoue H
    J Cardiovasc Pharmacol; 2005 Nov; 46(5):713-20. PubMed ID: 16220080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.
    Bijl MJ; Visser LE; van Schaik RH; Kors JA; Witteman JC; Hofman A; Vulto AG; van Gelder T; Stricker BH
    Clin Pharmacol Ther; 2009 Jan; 85(1):45-50. PubMed ID: 18784654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pharmacogenetics of β-adrenergic receptor antagonists in the treatment of hypertension and heart failure.
    Chan SW; Hu M; Tomlinson B
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):767-90. PubMed ID: 22621216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [For the first time beta blockers are in direct comparison With carvedilol weak hearts beat longer].
    MMW Fortschr Med; 2003 Jul; 145(27-28):60. PubMed ID: 14587195
    [No Abstract]   [Full Text] [Related]  

  • 11. beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.
    Terra SG; Pauly DF; Lee CR; Patterson JH; Adams KF; Schofield RS; Belgado BS; Hamilton KK; Aranda JM; Hill JA; Yarandi HN; Walker JR; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2005 Mar; 77(3):127-37. PubMed ID: 15735607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics.
    Sehrt D; Meineke I; Tzvetkov M; Gültepe S; Brockmöller J
    Pharmacogenomics; 2011 Jun; 12(6):783-95. PubMed ID: 21599570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of beta-adrenergic antagonists (atenolol, metoprolol tartrate, carvedilol) on the risk of rehospitalization in adults with heart failure.
    Go AS; Yang J; Gurwitz JH; Hsu J; Lane K; Platt R
    Am J Cardiol; 2007 Aug; 100(4):690-6. PubMed ID: 17697830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
    Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
    Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing beta-blockers in heart failure: when is a class not a class?
    Aronson JK
    Br J Gen Pract; 2008 Jun; 58(551):387-9. PubMed ID: 18505613
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug therapy of chronic heart failure: when are beta receptor blockers indicated?].
    vom Dahl J; Schotten U; Sasse A
    Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S48-53. PubMed ID: 10535047
    [No Abstract]   [Full Text] [Related]  

  • 18. Beta-blockers for heart failure: why you should use them more.
    Ong HT; Kow FP
    J Fam Pract; 2011 Aug; 60(8):472-7. PubMed ID: 21814642
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics.
    Kirchheiner J; Heesch C; Bauer S; Meisel C; Seringer A; Goldammer M; Tzvetkov M; Meineke I; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2004 Oct; 76(4):302-12. PubMed ID: 15470329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.
    Lymperopoulos A; McCrink KA; Brill A
    Curr Drug Metab; 2015; 17(1):30-6. PubMed ID: 26537419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.